ArticleIET nanobiotechnology2026
Exploring the Antiviral Potential of Tungsten Oxide Nanoparticles Against Herpes Simplex Virus Type 1: A Promising Alternative to Acyclovir.
Article in IET nanobiotechnology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Exploring the Antiviral Potential of Tungsten Oxide Nanoparticles Against Herpes Simplex Virus Type 1: A Promising Alternative to Acyclovir.IET nanobiotechnology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Herpes simplex virus type 1 (HSV-1) is responsible for the majority of cold sores, herpetic keratitis-induced blindness, profound skin lesions, and encephalitis that can be fatal. Currently, acyclovir and its derivatives are the first-line therapy for the treatment of HSV-1 infection. But there are drawbacks to these treatments: limited efficacy against drug-resistant strains of the virus. Hence, it is of critical importance to explore and develop new antiviral drugs for HSV-1. In the present study, we explored whether tungsten oxide nanoparticles (WO
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.